Intravenous immunoglobulin plus corticosteroids prevent coronary artery abnormalities in Kawasaki disease
- 1University College London, Institute of Child Health, London, UK
- 2Department of Paediatrics, Imperial College London, London, UK
- Correspondence to: Dr Paul Brogan
UCL Institute of Child Health, 30 Guilford Street, London, WC1N 1EH, UK;
Commentary on: Chen S, Dong Y, Yin Y, et al. Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis. Heart 2013;99:76–82.
Kawasaki disease (KD) is a medium vessel vasculitis affecting approximately 8 of 100 000 children under the age of 5 per year in the UK. It is the commonest cause of acquired heart disease in children in developed countries.1 The cause remains elusive. KD is associated with coronary artery aneurysms (CAA) in over 20% of untreated patients; intravenous immunoglobulin (IVIG) reduces CAA frequency to 5%. Only 2–3% of untreated cases die as a result of coronary vasculitis, and KD is an important cause of long-term cardiac disease in adult life. Patients who do not respond …